Implementation of rotavirus surveillance and vaccine introduction — World Health Organization African Region, 2007–2016

Author: Jason M. Mwenda et al.
Category: Service delivery

Abstract

Rotavirus is a leading cause of severe pediatric diarrhea globally, estimated to have caused 120,000 deaths among children aged <5 years in sub-Saharan Africa in 2013 (1). In 2009, the World Health Organization (WHO) recommended rotavirus vaccination for all infants worldwide (2). Two rotavirus vaccines are currently licensed globally: the monovalent Rotarix vaccine (RV1, GlaxoSmithKline; 2-dose series) and the pentavalent RotaTeq vaccine (RV5, Merck; 3-dose series). This report describes progress of rotavirus vaccine introduction (3), coverage (using estimates from WHO and the United Nations Children’s Fund [UNICEF]) (4), and impact on pediatric diarrhea hospitalizations in the WHO African Region. By December 2016, 31 (66%) of 47 countries in the WHO African Region had introduced rotavirus vaccine, including 26 that introduced RV1 and five that introduced RV5. Among these countries, rotavirus vaccination coverage (completed series) was 77%, according to WHO/UNICEF population-weighted estimates. In 12 countries with surveillance data available before and after vaccine introduction, the proportion of pediatric diarrhea hospitalizations that were rotavirus-positive declined 33%, from 39% preintroduction to 26% following rotavirus vaccine introduction. These results support introduction of rotavirus vaccine in the remaining countries in the region and continuation of rotavirus surveillance to monitor impact.

About

Type Journal article
Language English
Country Not Specified
PubMed URL http://www.cdc.gov/mmwr/volumes/66/wr/pdfs/mm6643a7-H.pdf
Journal Morbidity and Mortality Weekly Report
Volume 66
Year 2017
Added by Moderator
Added on 9 November 2017 12:14:14
Hits: 52
Rating Summary:
0 based on 0 votes
Add to Favourites